You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博安生物(06955.HK)午後曾升36% 自主開發血糖藥擬交上市申請
阿思達克 03-08 14:12
博安生物(06955.HK)今日高開3.17%,午後升幅擴大,最高見14.58元,一度升36%,見今年1月以來新高。現報12.16元,升13.43%,成交186.32萬股,涉資2,443.47萬元。 公司中午公佈,自主開發的度拉糖(月太)注射液(BA5101)已在中國完成III期臨牀試驗(臨牀有效性、安全性和免疫原性比對研究),並計劃遞交上市申請。 BA5101爲度易達的生物類似藥,用於成人2型糖尿病患者的血糖控制。就公司所知,BA5101是全球首個完成III期臨牀試驗的度拉糖(月太)生物類似藥,開發進度領先。(cy/k) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account